EMENDO
DEAD

Serial Number

90798013

Owner

EmendoBio Inc.

Attorney

LAUREN GREGORY LEIPOLD

Filing Date

Jun 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EMENDO Trademark

Serial Number: 90798013

EMENDO is a trademark filed by EmendoBio Inc. on June 28, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

EmendoBio Inc. (3 trademarks)

4th Floor
New York, NY 10069

Entity Type: 03

Trademark Details

Filing Date

June 28, 2021

Registration Date

Not Registered

Published for Opposition

December 27, 2022

Goods & Services

Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders

Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research

Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services, excluding production technologies; pharmaceutical research and development, excluding production technologies; pharmaceutical products development; pharmaceutical product evaluation; pharmaceutical drug development services, excluding production technologies; development of pharmaceutical preparations and medicines; technical research in the field of pharmaceutical studies, excluding production technologies; research and development in the pharmaceutical and biotechnology fields, excluding production technologies; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research services in the field of cancer; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; medical and scientific research in the field of cancer treatment and diagnosis; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
Mar 24, 2025 MAB4
ABANDONMENT - AFTER INTER PARTES DECISION
Mar 24, 2025 ABN4
OPPOSITION TERMINATED NO. 999999
Mar 24, 2025 OP.T
OPPOSITION DISMISSED NO. 999999
Mar 24, 2025 OP.D
ASSIGNED TO EXAMINER
Mar 10, 2025 DOCK
OPPOSITION INSTITUTED NO. 999999
Jun 26, 2023 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 24, 2023 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 22, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 3, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 3, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 18, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 10, 2021 NWOS
NEW APPLICATION ENTERED
Jul 1, 2021 NWAP